DexCom Financials - Benzinga

DexCom Inc

DXCMNASDAQ

Trade with Public

Trade with Public

$89.68

-0.01-0.01%

最終更新: Sep 3, 11:14 AM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

DexCom Financials

DexCom (DXCM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
DexCom Raises FY2026 Sales Guidance from $5.160B-$5.250B to $5.180B-$5.250B vs $5.224B Est

DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billion-$5.250 billion vs $5.224 billion estimate.

Benzinga Newsdesk

PRO
DexCom Q2 Adj. EPS $0.70 Beats $0.61 Estimate, Sales $1.308B Beat $1.290B Estimate

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.61 by 14.75 percent. This is a 45.83 percent increase over earnings of $0.48 per share from the same

Benzinga Newsdesk

Diabetes Tech Player DexCom Lays Out 2030 Growth Vision

DexCom Sets 2030 Margin Targets, Projects Double-Digit Revenue Growth, Authorizes $1 Billion Share Buyback

Vandana Singh

PRO
DexCom Affirms FY2026 Sales Guidance of $5.160B-$5.250B vs $5.230B Est

2026 Annual GuidanceDexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following

Benzinga Newsdesk

PRO
DexCom Q1 Adj. EPS $0.56 Beats $0.47 Estimate, Sales $1.191B Beat $1.175B Estimate

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.47 by 19.15 percent. This is a 75 percent increase over earnings of $0.32 per share from the same period

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved